Harvard Bioscience (NASDAQ:HBIO) Earns “Sell (E+)” Rating from Weiss Ratings

Harvard Bioscience (NASDAQ:HBIO)‘s stock had its “sell (e+)” rating reiterated by research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other analysts have also recently commented on the stock. Benchmark dropped their price target on shares of Harvard Bioscience from $3.00 to $2.00 and set a “speculative buy” rating on the stock in a research note on Wednesday, September 10th. Wall Street Zen cut shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, August 30th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $2.00.

Harvard Bioscience Stock Up 1.4%

HBIO opened at $0.44 on Wednesday. The stock has a market cap of $19.79 million, a price-to-earnings ratio of -0.34 and a beta of 1.52. The company’s 50-day moving average price is $0.47 and its two-hundred day moving average price is $0.45. Harvard Bioscience has a twelve month low of $0.28 and a twelve month high of $2.82.

Institutional Trading of Harvard Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Harvard Bioscience by 44.4% during the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after acquiring an additional 11,948 shares during the period. Landscape Capital Management L.L.C. bought a new stake in Harvard Bioscience during the 1st quarter worth approximately $33,000. Jane Street Group LLC increased its holdings in shares of Harvard Bioscience by 491.9% in the 2nd quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 58,785 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Harvard Bioscience by 221.1% in the 1st quarter. Deutsche Bank AG now owns 75,985 shares of the medical instruments supplier’s stock worth $43,000 after buying an additional 52,319 shares during the last quarter. Finally, Williams & Novak LLC increased its holdings in shares of Harvard Bioscience by 37.0% in the 2nd quarter. Williams & Novak LLC now owns 106,570 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 28,800 shares during the last quarter. Institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.